[HTML][HTML] Protection against omicron (B. 1.1. 529) BA. 2 reinfection conferred by primary omicron BA. 1 or pre-omicron SARS-CoV-2 infection among health-care …

…, S Barkati, C Sauvageau, N Brousseau… - The Lancet Infectious …, 2023 - thelancet.com
Background There is a paucity of data on vaccine-induced or infection-induced (hybrid or
natural) immunity against omicron (B.1.1.529) subvariant BA.2, particularly in comparing the …

Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec …

…, N Prystajecky, JR Tyson, R Gilca, N Brousseau… - MedRxiv, 2021 - medrxiv.org
Background The Canadian COVID-19 immunization strategy deferred second doses and
allowed mixed schedules. We compared two-dose vaccine effectiveness (VE) by vaccine type (…

[PDF][PDF] Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses

…, R Bazin, M Dubé, G De Serres, N Brousseau… - Cell host & …, 2022 - cell.com
The standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two doses
administered three weeks apart. However, some public health authorities spaced these …

Estimated protection of prior SARS-CoV-2 infection against reinfection with the Omicron variant among messenger RNA–vaccinated and nonvaccinated individuals in …

…, M Brisson, C Sauvageau, N Brousseau… - JAMA network …, 2022 - jamanetwork.com
Importance The Omicron variant is phylogenetically and antigenically distinct from earlier
SARS-CoV-2 variants and the original vaccine strain. Protection conferred by prior SARS-CoV-…

Two-dose severe acute respiratory syndrome coronavirus 2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies …

…, JR Tyson, R Gilca, N Brousseau… - Clinical Infectious …, 2022 - academic.oup.com
Background The Canadian coronavirus disease 2019 (COVID-19) immunization strategy
deferred second doses and allowed mixed schedules. We compared 2-dose vaccine …

SARS-CoV-2 seroprevalence in health care workers from 10 hospitals in Quebec, Canada: a cross-sectional study

N Brousseau, L Morin, M Ouakki, P Savard, C Quach… - Cmaj, 2021 - Can Med Assoc
Background: The COVID-19 pandemic has disproportionately affected health care workers.
We sought to estimate SARS-CoV-2 seroprevalence among hospital health care workers in …

Higher risk of measles when the first dose of a 2-dose schedule of measles vaccine is given at 12–14 months versus 15 months of age

…, N Boulianne, F Defay, N Brousseau… - Clinical infectious …, 2012 - academic.oup.com
Background. In 2011, >750 cases of measles were reported in Quebec, Canada, where a
routine 2-dose measles immunization schedule, in which measles vaccine is given at 12 and …

Single-dose effectiveness of mpox vaccine in Quebec, Canada: test-negative design with and without adjustment for self-reported exposure risk

N Brousseau, S Carazo, Y Febriani… - Clinical Infectious …, 2024 - academic.oup.com
Introduction During the 2022 mpox outbreak, the province of Quebec, Canada, prioritized
first doses for pre-exposure vaccination of people at high mpox risk, delaying second doses …

Protection against Omicron re-infection conferred by prior heterologous SARS-CoV-2 infection, with and without mRNA vaccination

…, M Brisson, C Sauvageau, N Brousseau… - medRxiv, 2022 - medrxiv.org
Importance Omicron is phylogenetically- and antigenically-distinct from earlier SARS-CoV-2
variants and the original vaccine strain. Protection conferred by prior SARS-CoV-2 infection …

[HTML][HTML] Increase of invasive pneumococcal disease in children temporally associated with RSV outbreak in Quebec: a time-series analysis

…, R Gilca, C Quach, N Brousseau… - The Lancet Regional …, 2023 - thelancet.com
Background Respiratory viruses have been previously suspected to trigger invasive
pneumococcal disease (IPD). After progressive non-pharmaceutical interventions (NPI) lifting, an …